Advertisement

Clinical Pharmacokinetics

, Volume 10, Issue 4, pp 315–333 | Cite as

Clinical Pharmacokinetics of the Depot Antipsychotics

  • Michael W. Jann
  • Larry Ereshefsky
  • Stephen R. Saklad
Review Article

Summary

The clinical pharmacokinetics of the 4 depot antipsychotics for which plasma level studies are available (i.e. fluphenazine enanthate and decanoate, haloperidol decanoate, clopenthixal decanoate and flupenthixol decanoate) are reviewed. The proper study of these agents has been handicapped until recently by the necessity of accurately measuring subnanomolar concentrations in plasma. Their kinetic properties, the relationship of plasma concentrations to clinical effects, and conversion from oral to injectable therapy are discussed.

The depot antipsychotics are synthesised by esterification of the active drug to a long chain fatty acid and the resultant compound is then dissolved in a vegetable oil. The absorption rate constant is slower than the elimination rate constant and therefore, the depot antipsychotics exhibit ‘flip-flop’ kinetics where the time to steady-state is a function of the absorption rate, and the concentration at steady-state is a function of the elimination rate.

Fluphenazine is available as both an enanthate and decanoate ester (both dissolved in sesame oil), although the decanoate is more commonly used clinically. The enanthate produces peak plasma concentrations on days 2 to 3 and declines with an apparent elimination half-life (i.e. the half-time of the apparent first-order decline of plasma concentrations) of 3.5 to 4 days after a single injection. The decanoate produces an early high peak which occurs during the first day and then declines with an apparent half-life rangingfrom 6.8 to 9.6 days following a single injection. After multiple injections of fluphenazine decanoate, however, the mean apparent half-life increases to 14.3 days, and the time to reach steady-state is 4 to 6 weeks. Withdrawal studies with fluphenazine decanoate suggest that relapsing patients have a more rapid plasma concentration decline than non-relapsing patients, and that the plasma concentrations do not decline smoothly but may exhibit ‘lumps’ due to residual release from previous injection sites or multicompartment redistribution. Cigarette smoking has been found to be associated with a 2.33-fold increase in the clearance of fluphenazine decanoate. In 3 different studies, fluphenazine has been proposed to have a therapeutic range from < 0.15 to 0.5 ng/ml with an upper therapeutic range of 4.0 ng/ml. Plasma concentrations following the decanoate injection are generally lower than, but clinically equivalent to, those attained with the oral form of the drug.

Haloperidol decanoate plasma concentrations peak on the seventh day following injection although, in some patients, this peak may occur on the first day. The apparent elimination half-life after multiple injections is approximately 3 weeks and the time to reach steady-state is approximately 3 months. The reduced metabolite of haloperidol is present in significant quantities in humans following oral therapy; however, this has not been reported in pharmacokinetic studies with the depot preparation. The therapeutic range for haloperidol has been reported to be 3 to 40 ng/ml in several studies, but these studies did not measure the reduced metabolite. It has been suggested that the presence of high concentrations of the reduced metabolite may affect the response to haloperidol.

Clopenthixol is only active as the cis (Z) isomer, which is the form of the drug present in the decanoate preparation. Peak plasma concentrations are usually reached between 4 and 7 days after injection. Following multiple injections, the apparent elimination half-life is 19 days. No correlation between plasma concentrations and clinical response has been reported, but concentrations have been observed to range from 10 to 100 ng/ml following a wide range of dosages and injection intervals.

Flupenthixol is available as either the palmitate or decanoate ester, although most pharmacokinetic studies have used the decanoate formulation. Like clopenthixol, flupenthixol is only active as the cis (Z) isomer which is the form present in the decanoate preparation. Peak plasma concentrations occur on approximately the seventh day following injection, and no pharmacokinetic differences have been observed between the 2% and 10% concentrations of the drug. Following a single injection, an apparent elimination half-life of 8 days was reported, whereas after multiple injections, the apparent half-life was 17 days. Following withdrawal, no statistically significant differences were noted between relapsing and non-relapsing patients, but there was a trend towards lower trough concentrations in the relapsing group. There was also a shorter apparent half-life in the relapsing group when compared with the non-relapsing patients. No correlations between plasma concentrations and clinical response were found.

Most methods for converting oral preparations to depot injections have been empirically developed. One study that did examine plasma concentrations and clinical effects during conversion of oral fluphenazine to the decanoate found that 1.2 to 2.5 times the oral dose (mg/day) given weekly resulted in a smooth transition between dosage forms. Fluphenazine plasma concentrations on the decanoate were lower during the first 3 weeks in comparison with oral fluphenazine therapy. It is recommended that the initially effective dose be reduced or the injection interval increased after 4 to 6 weeks to prevent possible accumulation of drugs as plasma concentrations approach steady-state. The recommended dose of haloperidol decanoate is 20 times that of the daily oral dose (mg/day) given monthly, but this should be reduced to a factor of 15 in geriatric patients. Flupenthixol 10mg given orally daily is proposed to be equivalent to 25mg of the decanoate given weekly. The use of the mean conversion ratios as a starting point for an individual patient’s conversion is appropriate, but wide interindividual variations in pharmacokinetics require plasma level monitoring and careful clinical observation of the patient.

Adverse effects from depot antipsychotics are relatively rare, except for extrapyramidal system reactions. The most serious (albeit very rare) problem that can occur with a long acting antipsychotic is the neuroleptic malignant syndrome. Due to their long apparent half-lives after injection, effective treatment of this syndrome following administration of depot antipsychotics can be difficult.

Keywords

Haloperidol Clinical Pharmacokinetic Decanoate Fluphenazine Enanthate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Aaes-Jørgensen, T.: Specific high-performance liquid Chromatographic method for estimation of the cis(z)- and trans(e)-isomers of clopenthixol and a N-dealkyl metabolite. Journal of Chromatography 183: 239–245 (1980).PubMedCrossRefGoogle Scholar
  2. Aaes-Jørgensen. T.: Kirk. L.; Petersen, E.; Danneskiod-Samsoe, P. and Jørgensen. A.: Serum concentrations of the isomers of clopenthixol and a metabolite in patients given cis(z)-clopenthixol decanoate in viscoleo. Psychopharmacology 81: 68–72 (1983).PubMedCrossRefGoogle Scholar
  3. Aacs-Jørgensen. T.; Overo, K.F.: Gobeso. K.P. and Jørgensen, A.: Pharmacokinetic studies on clopenthixol decanoate: A comparison with clopenthixol in dogs and rats. Acta Pharmacologica et Toxicologica 41: 103–120 (1977).CrossRefGoogle Scholar
  4. Altamura. A.C.: Whelpton, R. and Curry, S.H.: Animal model for investigation of fluphenazine kinetics after administration of long-acting esters. Biopharmaceutics and Drug Disposition 1: 65–72 (1979).CrossRefGoogle Scholar
  5. Amdisen, A. and Thomsen, N.J.: Drug levels after withdrawal of long-term depot neuroleptics. Lancet 2: 1425 (1981).CrossRefGoogle Scholar
  6. Blaschke, T.F.: Protein binding and kinetics of drugs in liver diseases. Clinical Pharmacokinetics 2: 32–44 (1977).PubMedCrossRefGoogle Scholar
  7. Bennett, W.M.; Muther, R.S.; Parker, R.A.; Feid, P.; Morrison, G.: Golpher. T.A. and Singer, I.: Drug therapy in renal failure: Dosing guidelines for adults. Part II. Annals of Internal Medicine 93: 286–325 (1980).PubMedGoogle Scholar
  8. Bond, W.S.: Clinical relevance of the effect of hepatic disease on drug disposition. American Journal of Hospital Pharmacy 35: 406–414 (1978).PubMedGoogle Scholar
  9. Browning, J.L.; Silverman, P.B.; Harrington, C.A. and Davis, C.M.: Preliminary behavioral and pharmacological studies on the haloperidol metabolite reduced haloperidol. (Abstract.) Society for Neuroscience 8: 470 (1982).Google Scholar
  10. Caroff. S.N.: The neuroleptic malignant syndrome. Journal of Clinical Psychiatry 41: 79–83 (1980).PubMedGoogle Scholar
  11. Cheung. H.K. and Yu, E.C.S.: Effect of 1050mg fluphenazine decanoate given intramuscularly over six days. British Medical Journal 286: 1016–1017 (1983).PubMedCrossRefGoogle Scholar
  12. Cooper. T.M.: Plasma level monitoring of antipsychotic drugs. Clinical Pharmacokinetics 3: 14–38 (1978).PubMedCrossRefGoogle Scholar
  13. Curry, S.H.: Altamura, A.C. and Montgomery, S.: Unwanted effects of fluphenazine enanthate and decanoate. Lancet 1: 331–332 (1979b).PubMedCrossRefGoogle Scholar
  14. Curry. S.H.: Whelpton, R.; de Schepper, P.J.; Vranckx, S. and Schiff, A.A.: Plasma fluphenazine concentrations after injection of long-acting esters. Lancet 1: 1217–1315 (1976).Google Scholar
  15. Curry. S.H., Whelpton, R.; de Schepper, P.J.; Vranckx, S. and Schiff, A.A.: Kinetics of fluphenazine after fluphenazine dihydrochloride, enanthate and decanoate administration to man. British Journal of Clinical Pharmacology 7: 325–331 (1979a).PubMedCrossRefGoogle Scholar
  16. Davis. C.M. and Fenimore, D.C.: Determination of fluphenazine in plasma by high-performance thin-layer chromatography. Journal of Chromatography 272: 157–165 (1983).PubMedCrossRefGoogle Scholar
  17. Deberdt, R.; Elens, P.; Berghmans, W.; Heykants, J.; Woestenborghs, R.; Drelsens, F.; Reyntijens, A. and Wijngaarden, I.: Intramuscular haloperidol decanoate for neuroleptic maintenance therapy, efficacy, dosage schedule and plasma levels. Acta Psychiatrica Scandinavica 62: 356–363 (1980).PubMedCrossRefGoogle Scholar
  18. Dencker. S.J.; Johannsson, R.; Lundin, L. and Malm, U.: High doses of fluphenazine enanthate in schizophrenia. Acta Psychiatrica Scandinavica 57: 405–414 (1978).PubMedCrossRefGoogle Scholar
  19. Dencker, S.J.; Malm, U.; Jørgensen, A. and Overø, K.F.: Clopenthixol and flupenthixol depot preparations in outpatient schizophrenics. IV. Serum levels and clinical outcome. Acta Psychiatrica Scandinavica (Suppl.) 279: 55–63 (1980).Google Scholar
  20. De Schepper. P.J.; Vranckx, C.:, Verbeeck, R. and Van den Berghe, M.L.O.: Pipotiazine pharmacokinetics after p.o. and i.v. administration in man. Arzneimittel-Forschung 29: 1056–1062 (1979).PubMedGoogle Scholar
  21. Donlon. P.T.: Axelrad, A.D.; Tupin, J.P. and Chien, C.: Comparison of depot fluphenazines: Duration of action and incidence of side effects. Comprehensive Psychiatry 17: 369–375 (1976).PubMedCrossRefGoogle Scholar
  22. Dreyfuss. J.: Ross. J.J. and Schreiber, E.C.: Excretion and biotransformation of the enanthate ester of fluphenazine-14C by the dog. Journal of Pharmaceutical Sciences 60: 829–833 (1971).PubMedCrossRefGoogle Scholar
  23. Dreyfuss. J.: Ross. J.J.: Shaw, J.M.; Miller, I. and Schreiber, E.C.: Release and elimination of 14C-fluphenazine enanthate and decanoate esters administered in sesame oil to dogs. Journal of Pharmaceutical Sciences 65: 502–507 (1976b).PubMedCrossRefGoogle Scholar
  24. Dreyfuss, J.: Shaw, J.M. and Ross, R.R.: Fluphenazine enanthate and fluphenazine decanoate: Intramuscular injections and esterification as requirements for slow-release characteristics in dogs. Journal of Pharmaceutical Sciences 65: 1310–1315 (1976a).PubMedCrossRefGoogle Scholar
  25. Dudley, J.: Rauw, G.; Hawes, E.M.; Keegan, D.L. and Midha, K.K.: Correlation of fluphenazine plasma levels versus clinical response in patients: A pilot study. Progress in Neuro-Psychopharmacology and Biological Psychiatry 7(4-6): 791–795 (1983).PubMedCrossRefGoogle Scholar
  26. Dysken. M.W.; Chang, S.S.; Schaffer, C.; Casper, R.C.; Javaid, J.I. and Davis, J.M.: Plasma levels and therapeutic efficacy of fluphenazine hydrochloride and decanoate; in Cattabeni (Ed.) Advances in Biochemical Psychopharmacology, Vol. 24, pp. 581–583 (Raven Press, New York 1980).Google Scholar
  27. Dysken, M.W.; Javaid, J.I.; Chang, S.S.; Schaffer, C.; Shahid, A. and Davis. J.M.: Fluphenazine pharmacokinetics and clinical response. Psychopharmacology 73: 205–210 (1981).PubMedCrossRefGoogle Scholar
  28. Ereshefsky, L.; Davis, C.M.; Harrington, C.A.; Jann, M.W.; Browning. J.L.; Saklad. S.R. and Burch, N.R.: Haloperidol and reduced haloperidol plasma levels in selected schizophrenic patients. Journal of Clinical Psychopharmacology 4: 138–142 (1984b).PubMedCrossRefGoogle Scholar
  29. Ereshefsky. L.; Jann. M.W.; Saklad, S.R.; Davis, C.M.; Richards, A.L. and Burch, N.R.: Effects of smoking on fluphenazine clearance in psychiatric inpatients. Biological Psychiatry 20: 329–332 (1985b).PubMedCrossRefGoogle Scholar
  30. Ereshefsky. L.; Richards, A.L.; Grothe, D.R.; Saklad, S.R. and Jann. M.W.: Pharmacokinetic and clinical evaluation of the conversion from oral to depot fluphenazine. Unpublished data (1985a).Google Scholar
  31. Ereshefsky, L.; Saklad, S.R.: Davis, C.M.; Jann, M.W.; Richards, A.L. and Burch, N.R.: Clinical implications of fluphenazine pharmacokinetics. Monograph, The University of Texas, 1984c.Google Scholar
  32. Ereshefsky. L.; Saklad, S.R.; Jann, M.W.; Davis, C.M.; Richards, A.L. and Seidel, D.R.: Future of depot neuroleptic therapy: Pharmacokinetic and pharmacodynamic approaches. Journal of Clinical Psychiatry 45 (Suppl.): 50–59 (1984a).PubMedGoogle Scholar
  33. Ereshefsky. L.: Saklad, S.R.; Jann, M.W.; Richards, A.L. and Davis, C.M.: Pharmacokinetics of fluphenazine by high performance thin layer chromatography. Drug Intelligence and Clinical Pharmacy 17: 436–437 (1983).Google Scholar
  34. Escobar, J.I.; Barron, A. and Kiriakos, R.: Serum levels of fluphenazine: Effect of dosage and route of administration and relations to side effects and clinical response. Psychopharmacology Bulletin 19: 131–133 (1983).Google Scholar
  35. Forsman. A.: Folsch, G.; Larsson, M. and Ohman, R.: On the metabolism of haloperidol in man. Current Therapeutic Research 21: 606–617 (1977).Google Scholar
  36. Forsman. A. and Larsson. M.: Metabolism of haloperidol. Current Therapeutic Research 24: 567–568 (1978).Google Scholar
  37. Forsman. A. and Ohman. R.: Pharmacokinetic studies on haloperidol in man. Current Therapeutic Research 20: 319–336 (1976).PubMedGoogle Scholar
  38. Fredricson-Overo, K.: A specific fluorimetric method for assay of drug levels in serum of patients treated with clopenthixol decanoate injections. Acta Psychiatrica Scandinavica (Suppl.) 279: 92–103 (1980).Google Scholar
  39. Gibaldi. M. and Perrier, P.: Pharmacokinetics, 2nd ed., Drugs and the Pharmaceutical Sciences, vol. 15, pp. 83–84 (Marcel Dekker Inc., New York 1982).Google Scholar
  40. Hansen. C.E.; Christensen. T.R.: Elley, J.; Hansen, L.B.; Kragh-Sorenscn, P.; Larsen. N.E.; Naesoft, J. and Hvidberg, E.F.: Clinical pharmacokinelic studies of perphenazine. British Journal of Clinical Pharmacology 3: 915–923 (1976).CrossRefGoogle Scholar
  41. Harris. P.Q.: Friedman. M.J.; Cohen, B.M. and Cooper, T.M.: Fluphenazine blood levels and clinical response. Biological Psychiatry 17: 1123–1130 (1982).PubMedGoogle Scholar
  42. Heykanls, J.: Prinsen. P. and Michiels, M.: Pharmacokinetics of haloperidol in beagle dogs after single and repeated intramuscular administration of haloperidol decanoate. Tissue distribution of haloperidol after repealed administration of haloperidol decanoate for six months. Preclinical Research Report (R 13 672/4). January 1981.Google Scholar
  43. Hollister. L.E. and Kim. D.Y.: Intensive treatment with haloperidol of treatment-resistant chronic schizophrenic patients. American Journal of Psychiatry 139: 1466–1468 (1982).PubMedGoogle Scholar
  44. Holt, R.J.: Fluphenazine decanoate-induced cholestatic jaundice and thrombocytopenia. Pharmacotherapy 4: 227–229 (1984).PubMedGoogle Scholar
  45. Jann. M.W.: Ereshefsky, L.; Saklad. S.R.; Richards, A.L. and Davis, C.M.: Haloperidol and reduced haloperidol plasma levels in schizophrenic patients. Drug Intelligence and Clinical Pharmacy 18: 507 (1984).Google Scholar
  46. Javors. M.A. and Bowden, C.L.: Intra- and inter-assay variation in radioreceptor assay for haloperidol. Clinical Pharmacology and Therapeutics 37: 27 (1985).Google Scholar
  47. Jinks. M.J.; Geriatric therapy; in Katcher et al. (Eds) Applied Therapeutics: The Clinical Use of Drugs, pp. 1513–1529 (Applied Therapeutics Inc., San Francisco and Spokane 1983).Google Scholar
  48. Jørgensen, A.: Pharmacokinetic studies on flupenthixol decanoate, a depot neuroleptic of the thioxanthine group. Drug Metabolism Reviews 8: 235–249 (1978a).PubMedCrossRefGoogle Scholar
  49. Jørgensen, A.: A sensitive and specific radioimmunoassay for cis(z)-flupemhixol in human serum. Life Sciences 23: 1533–1542 (1978b).PubMedCrossRefGoogle Scholar
  50. Jørgensen, A.: Pharmacokinetic studies in volunteers of intravenous and oral cis(z)-flupentixol and intramuscular cis(z)-flupentixol decanoate in Viscoleo. European Journal of Clinical Pharmacology 18: 355–360 (1980a).PubMedCrossRefGoogle Scholar
  51. Jørgensen, A.: The pharmacokinetics of cis(z)-flupentixol and cis(z)-flupenlixol decanoate; in Usdin et al. (Eds) Phenothiazines and Structurally Related Drugs: Basic and Clinical Studies, pp. 215–218 (Elsevier/North Holland, Amsterdam 1980b).Google Scholar
  52. Jørgensen. A.; Andersen, J.; Bjørndal, N.; Dencker, S.J.; Lundin, L. and Malm, U.: Serum concentrations of cis (z)-flupenthixol and prolactin in chronic schizophrenic patients treated with flupenthixol and cis (z)-flupenthixol decanoate. Psychopharmacology 77: 58–65 (1982).PubMedCrossRefGoogle Scholar
  53. Jørgensen, A. and Gottfries, C.G.: Pharmacokinetic studies on flupenthixol and flupenthixol decanoate in man using tritium labelled compounds. Psychopharmacology 27: 1–10 (1972).CrossRefGoogle Scholar
  54. Jørgensen, A. and Overo, K.F.: Clopenthixol and flupenthixol depot preparations in outpatient schizophrenics. III. Serum levels. Acta Psychiatrica Scandinavica 61 (Suppl. 279): 41–54 (1980).Google Scholar
  55. Jørgensen. A.; Overo, K.F. and Hansen, V.: Metabolism, distribution and excretion of flupenthixol decanoate in dogs and rats. Acta Pharmacologica et Toxicologica 29: 339–358 (1971).PubMedCrossRefGoogle Scholar
  56. Julou, L.; Bourat, G.; Ducrot, R.; Fournel, J.; Garret, C. and Mottet, F.: Correlations entre les resultats etudes pharmacologiques et pharmacocinetiques dans le cas de quelques esters de la pipatiazine. Therapie 28: 475–490 (1973).PubMedGoogle Scholar
  57. Kane, J.M.; Rifkin, A.; Quitkin, F.; Nayak, D.; Saraf, K.; Ramos-Lorcnzi, J.R.; Klein, D.F. and Sachar, E.J.: Low dose fluphenazine decanoate in maintenance treatment of schizophrenia. Psychiatry Research 1: 341–348 (1979).PubMedCrossRefGoogle Scholar
  58. Kane, J.M. and Smith, J.M.: Tardive dyskinesia. Prevalence and risk factors. 1959–1979. Archives of General Psychiatry 39: 473–481 (1982).PubMedCrossRefGoogle Scholar
  59. Korpi, E.R.: Phelps, B.H.; Granger, H.: Change, W.; Linnoila, M.; Meek, J.L. and Wyan, R.J.: Simultaneous determination of haloperidol and its reduced metabolite in scrum and plasma by isocratic liquid chromatography with electrochemical detection. Clinical Chemistry 29: 624–628 (1983).PubMedGoogle Scholar
  60. Korpi, E.R. and Wyatt, R.J.: Reduced haloperidol: Effects on striatal dopamine metabolism and conversion on haloperidol in the rat. Psychopharmacology 83: 34–37 (1984).PubMedCrossRefGoogle Scholar
  61. Larsson, M.: Forsman. A. and Ohman, R.: A high performance liquid Chromatographie method for the determination of haloperidol and reduced haloperidol in serum. Current Therapeutic Research 34: 999–1008 (1983).Google Scholar
  62. Magliozzi, J.R.; Hollister, L.E.; Arnold, K.V. and Earle, G.M. Relationship of serum haloperidol levels lo clinical response in schizophrenic patients. American Journal of Psychiatry 138: 365–367 (1981).PubMedGoogle Scholar
  63. Mason, A.S. and Granacher, R.P.: The depot fluphenazincs; in Clinical Handbook of Antipsychotic Drug Therapy, pp. 171–184 (Brunner/Mazel, New York 1980).Google Scholar
  64. Mavroids, M.L.; Kanter, D.R.; Hirschowitz, J. and Garver, D.L.: Clinical response and plasma haloperidol levels in schizophrenia. Psychopharmacology 81: 354–356 (1983).CrossRefGoogle Scholar
  65. Mavroids, M.I.: Kanter, D.R.; Hirschowitz, J. and Garver, D.L.: Therapeutic blood levels of fluphenazine or RBC determinations. Psychopharmacology Bulletin 20: 168–170 (1984).Google Scholar
  66. Meco, G.; Casacchia, M.; Attenni, M.; Iatrate, A.; Castellana, F. and Ecari, U.: Haloperidol decanoate in senizophreniform disorders. Acta Psychiatrica Belgium 83: 57–68 (1983).Google Scholar
  67. Midha, K.K.; Cooper, J.K. and Hubbard, J.W.: Radioimmunoassay for fluphenazine in human plasma. Communications in Psychopharmacology 4: 107–114 (1980).PubMedGoogle Scholar
  68. Miller, D.D.; Hershey, L.A.; Duffy, J.P.; Abernethy, D.F. and Greenblatt, D.J.: Serum haloperidol concentrations and clinical response in acute psychosis. Journal of Clinical Psychopharmacology 4: 305–310 (1984).PubMedCrossRefGoogle Scholar
  69. Mitchell and Gauthier Associates: ACSL User Guide/Reference Manual, Concord, Mass., 1975.Google Scholar
  70. Nasrallah, H.A.; Rivera-Calimlin, L.; Rogol, A.D.; Gillin, J.C. and Wyatt, R.J.: Fluphenazine decanoate and prolactin: Plasma concentrations and clinical response; in Gottschalk (Ed.) Pharmacokinetics of Psychoactive drugs: Further Studies, pp. 115–123 (Spectrum Publications, New York 1979).Google Scholar
  71. Nolen, W.A. and Borger, J.: Disturbances of liver function by long acting neuroleptic drugs. Pharmacopsychiatry 11: 199–201 (1978).CrossRefGoogle Scholar
  72. Pape, B.E.: Isolation and identification of a metabolite of haloperidol. Journal of Analytical Toxicology 5: 113–117 (1981).PubMedGoogle Scholar
  73. Parent, M.; Toussaint, C.H.; Driesens, F. and Gelders, Y.G.: Pharmacocinetique du décanoate d’haloperidol chez le psychotique. Acta Psychiatrica Belgium 81: 399–406 (1981).Google Scholar
  74. Pelckmans, A.D.: Double-blind study of changes in long-term patients under the influence of regularly fluctuating doses of fluphenazine decanoate; in Usdin et al. (Eds) Phenothiazines and Structurally Related Drugs: Basic and Clinical Studies, pp. 202–206 (Elsevier/North Holland, Amsterdam 1980).Google Scholar
  75. Raskind. M.A.; Alvarez, C.; Pietrzyk, M.; Westerlund, K. and Herlin, S.: Helping the elderly psychiatric patient in crisis. Geriatrics 31: 41–56 (1976).Google Scholar
  76. Read, A.E.; Laidlaw, J. and McCarthy, C.F.: Effects of chlorpromazine in patients with hepatic diseases. British Medical Journal 3: 497–499 (1969).PubMedCrossRefGoogle Scholar
  77. Rcyntijens, A.J.M.; Heykants, J.J.P.; Woestenborghs, R.J.H.; Gelders, Y.G. and Aerts, T.J.L.: Pharmacokinetics of haloperidol decanoate. International Pharmacopsychiatry 17: 238–246 (1982).Google Scholar
  78. Richards, M.F.; Actis Dato, A.C.; Zelascki, N.M.; Balbo, E.A. and Canero, E.C.: Monthly haloperidol decanoate substitute for daily neuroleptics in psychotic patients. Current Therapeutic Research 30: 586–589 (1983).Google Scholar
  79. Rivera-Calimlin, L. and Hershey, L.: Neuroleptic concentrations and clinical response. Annual Review of Pharmacology and Toxicology 24: 361–386 (1984).CrossRefGoogle Scholar
  80. Saikia, J.K. and Jørgensen, A.: Steady-state serum concentrations after cis(z)-flupcnthixol decanoate in Viscoleo. Psychopharmacology 8: 371–373 (1983).CrossRefGoogle Scholar
  81. Sicberns, S. and Spcchtmeyer, H.: Ciz (z)-clopenthixoldecanoatecin neues depot neurol eptikum. International Pharmacopsychiatry 17: 170–184 (1982).Google Scholar
  82. Simpson, G.M.: A brief history of depot neuroleptics. Journal of Clinical Psychiatry 45(5): 3–4 (1984).PubMedGoogle Scholar
  83. Stauning, J.A.; Kirk, L. and Jørgensen, A.: Comparison of serum levels after intramuscular injections of 2% and 10% cis (z)-flupcnthixol decanoale in viscoleo to schizophrenic patients. Psychopharmacology 65: 69–72 (1979).PubMedCrossRefGoogle Scholar
  84. Stimmel, G.L. and Falloon. I.R.H.: Chlorpromazine plasma levels, adverse effects and tobacco smoking: Case project. Journal of Clinical Psychiatry 44: 420–422 (1983).PubMedGoogle Scholar
  85. Svenden, O. and Aaes-Jørgensen, T.: Studies on the fate of vegetable oil after intramuscular injection into experimental animals. Acta Pharmacologica et Toxicologica 45: 352–378 (1979).CrossRefGoogle Scholar
  86. Tepper, S.J. and Haas, J.F.: Prevalence of tardive dyskinesia. Journal of Clinical Psychiatry 40: 508–516 (1979).PubMedGoogle Scholar
  87. Tune, L.E.; Creese, I.; Coyle, J.T.; Pearlson, G. and Synder, S.H.: Low neuroleptic serum levels in patients receiving fluphenazine decanoate. American Journal of Psychiatry 137: 80–82 (1980a).PubMedGoogle Scholar
  88. Tune, L.E.; Creese, I., DePaulo, J.R.; Slavney, P.R.; Coyle, J.T. and Snyder, S.H.: Clinical state and serum neuroleptic levels measured by radioreceptor assay in schizophrenia. American Journal of Psychiatry 137: 187–190 (1980b).PubMedGoogle Scholar
  89. Van Praag, H.M. and Dols, L.C.W.: Fluphenazine enanthate and fluphenazine decanoate: A comparison of their duration of action and motor side effects. American Journal of Psychiatry 130: 801–804 (1973).PubMedGoogle Scholar
  90. Viola, A.; Hou, H.; Ba, B.; Durand, A.; Dufour, H.; Agostino, N.D.; Berda, C. and Jørgensen, A.: Blood and plasma kinetics of cis (z)-clopenthixol and fluphenazine in psychiatric patients after intramuscular injection of their decanoic esters. Psychopharmacology 83: 147–150 (1984).CrossRefGoogle Scholar
  91. Viukari, M.; Salo, H.; Lamminsivu, U. and Gordin, A.: Tolerance and serum levels of haloperidol during parenteral and oral haloperidol treatment in geriatric patients. Acta Psychiatrica Scandinavica 65: 301–308 (1982).PubMedCrossRefGoogle Scholar
  92. Whclpton, R.J. and Curry, S.H.: Methods for study of fluphenazine kinetics in man. Journal of Pharmacy and Pharmacology 28: 869–873 (1976).CrossRefGoogle Scholar
  93. Wiles, D.; Franklin, M.; Dencker, S.J.; Johansson, R.; Lindin, L. and Malm, U.: Plasma fluphenazine and prolactin levels in schizophrenic patients during treatment with low and high doses of fluphenazine enanthate. Psychopharmacology 71: 131–136 (1980).PubMedCrossRefGoogle Scholar
  94. Wiles, D.H. and Gelder. M.G.: Plasma fluphenazine levels by radioimmunoassay in schizophrenic patients treated with depot injections of fluphenazine decanoate; in Cattabeni (Ed.) Advances in Biochemical Psychopharmacology, Vol. 24, pp. 599–602 (Raven Press, New York 1980).Google Scholar
  95. Wistedt, B.: A depot neuroleptic withdrawal study: A controlled study of the clinical effects of the withdrawals of depot fluphenazine decanoate and depot flupenthixol decanoate in chronic schizophrenic patients. Acta Psychiatrica Scandinavica 64: 65–84 (1981).PubMedCrossRefGoogle Scholar
  96. Wistedt, B.; Jørgensen, A. and Wiles, D.: A depot neuroleptic withdrawal study. Plasma concentration of fluphenazine and flupenthixol and relapse frequency. Psychopharmacology 78: 301–304 (1982).PubMedCrossRefGoogle Scholar
  97. Wistedt, B. and Ranta, J.: Comparative double-blind study of flupenthixol decanoate and fluphenazine decanoate in the treatment of patients relapsing in a schizophrenic symptomatology. Acta Psychiatrica Scandinavica 67: 378–388 (1983).PubMedCrossRefGoogle Scholar
  98. Wistedt, B.; Wiles, D. and Kolakowska, T.: Slow decline in plasma drug and prolactin levels after discontinuation of chronic treatment with depot neuroleptics. Lancet 1: 1163 (1981).PubMedCrossRefGoogle Scholar
  99. Young, D.; Ereshefsky, L.; Saklad. S.R.; Jann, M.W. and Garcia, N.: Explaining the pharmacokinetics of fluphenazine through computer simulations. (Abstract.) Presented at the 19th Annual Midyear Clinical Meeting of the American Society of Hospital Pharmacists, Dallas, Texas (1984).Google Scholar

Copyright information

© Adis Press Limited 1985

Authors and Affiliations

  • Michael W. Jann
    • 1
    • 2
    • 3
  • Larry Ereshefsky
    • 1
    • 2
    • 3
  • Stephen R. Saklad
    • 1
    • 2
    • 3
  1. 1.College of PharmacyThe University of TexasAustinUSA
  2. 2.Clinical Pharmacy Program, and Departments of Pharmacology and PsychiatryThe University of Texas Health Science CenterSan AntonioUSA
  3. 3.San Antonio State School and San Antonio State HospitalUSA

Personalised recommendations